Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

The European Melanoma Registry

EUMelaReg collects real-world data from melanoma patients throughout Europe and securely integrates these datasets in a common database.

Geographical coverage

Geographical coverage

14,700

Datasets available

17

Participating countries

News & Events

13,000 data sets in EUMelaReg

We are pleased to announce that we have reached the enormous number of 13,000 data sets in the European Melanoma Registry. This is the result of the constant work and commitment of everyone involved i...

New member at EUMelaReg: Welcome North Macedonia

We are happy to welcome a new member on board: North Macedonia has joined the Central and South Eastern European Melanoma Expert Group (CSEEMEG), becoming the 17th country to join EUMelaReg. With its...

Second EUMelaReg poster at SMR congress 2023

We are proud that another EUMelaReg project was accepted for poster presentation at the SMR congress this year: “Efficacy of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 t...

EUMelaReg PD-SEQ poster presented at SMR congress 2023

An EUMelaReg real world evidence study with the title “Upfront usage of single agent anti-PD1 antibodies versus combined BRAF and MEK inhibitors in metastatic or unresectable BRAF V600 mutated melanom...

EUMelaReg website: new section "Publications"

We are pleased to inform you that we have set up a new "Publications" area on our website. This section offers an insight into EUMelaReg scientific projects and publications. The poster of the EUMelaR...

EUMelaReg ADJU-SEQ poster presented at ESMO congress 2023

As part of the EUMelaReg ADJU-SEQ project a subanalysis was performed and accepted for poster presentation at the ESMO Congress 2023 in Madrid (Abstract title: Efficacy of immune checkpoint inhibition...

Join us!

Collecting real-world data from melanoma patients across Europe, we aim to build the largest and quickest melanoma registry in the world. Interested societies or cancer treatment centres can help us by joining EUMelaReg – even without an existing registry.

“While the total number of cancer incidences is dropping, the number of cases of melanoma is increasing at a rate of 3-7% in many European countries. We need to analyse more data in order to improve diagnosis and develop novel therapies.”

Lidija Kandolf, Serbia

“A rapidly accumulating and massive high-quality real-life data can be obtained only when hands are joined. The conclusions we get from analysing such data allow us to better understand skin cancers and treatment effects. It allows us to formulate burning and important clinical questions and receive the results promptly, in real-time. This is a huge advantage that takes us one step further toward curing cancer. I'm proud to take part in this international collaborative project!”

Nethanel Asher, Israel

“Our advances and success in melanoma research are the result of a true team effort including international collaborations. World class cancer registries are highly needed for patient stratification strategies, as well as in order to translate the results of clinical trials in unselected patient populations and monitor patient care.”

Johanna Mangana, Switzerland

“Real-world data is crucial to validate clinical trial data. Generally, patients enrolled in clinical trials are selected in comparison to patients treated in real life (who are often in worse condition). Analysing data from a large number of real-life patients allows us to assess the true impact of new therapies in clinical practice. This is why a clinical registry such as the European Melanoma Registry is essential.”

Paolo Ascierto, Italy

“In recent years, we have witnessed revolutionary breakthroughs in treatment as well as rejuvenation of patients with melanoma, which poses new challenges for us. EUMelaReg has evolved into a valuable and even more powerful platform for in-depth analysis of clinical practice so far, enabling us to achieve better understanding and successful management of the condition. We are delighted to contribute to global knowledge with data from our real-world practice in Bulgaria.”

Iva Gavrilova, Bulgaria

“The agreement between Germany, Holland and Denmark in December 2017 to establish a European real-world clinical database on metastatic melanoma has proven its value. National databases in several European countries have since been established, and the growing number of patients in the EUMelareg database already have led to significant scientific contributions in the field of real-world evidence. These contributions is of utmost importance to confirm data from pivotal clinical trials on new drugs in melanoma treatment.”

Lars Bastholt, Denmark

“Being part of European Melanoma Registry enables us to gain deeper knowledge that not only refines our diagnosis and treatment strategies but by prioritizing accurate data, we also aim to significantly improve the quality of life and increase the survival rates of melanoma patients.”

Ermira Vasili, Albania

Benefits

Implementation of national registries

Provision of infrastructure

Data analysis through reknowned experts

Improved diagnosis and treatment

Consortium

ADO

German Skin Cancer Society

GEM

Spanish Multidisciplinary Melanoma Group

DMTR

Dutch Melanoma Treatment Registry

DAMMED

Danish Oncology Melanoma Database

CSEEMEG

Central South Eastern European Melanoma Expert Group

RoMelaReg

Romanian Melanoma Registry

SwiMelaReg

Swiss Melanoma Registry

PSSO

Polish Society of Surgical Oncology

HESMO

Hellenic Society of Medical Oncology

CNMR

Clinical National Melanoma Registry

BADO

Bulgarian Association of Dermato-Oncology

Ella Lemelbaum Institute for Immuno-Oncology and Melanoma

ALMelaReg

Albanian Melanoma Registry